Brain metastases from breast cancer: Management approach

Journal of Cancer Research and Therapeutics

Volumn 3, Issue 3, 2007, Pages 157-165

  Wadasadawala, Tabassum ^a   Gupta, Sudeep ^a   Bagul, Vaishali ^a   Patil, Namrata ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Brain metastases; Radiation; surgery; Targeted therapy

Indexed keywords

CAPECITABINE; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LAPATINIB; LOBRADIMIL; MANNITOL; METHOTREXATE; NAVELBINE; PREDNISOLONE; STEROID; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB;

ADJUVANT THERAPY; ANTICONVULSANT THERAPY; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM METASTASIS; CONSTIPATION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; HUMAN; LEPTOMENINX; LEUKOPENIA; LOADING DRUG DOSE; MORBIDITY; MULTIPLE CYCLE TREATMENT; ONCOGENE NEU; PALLIATIVE THERAPY; PATHOGENESIS; PATIENT CARE; PNEUMONIA; PROTEIN TARGETING; RADIOSENSITIZATION; REVIEW; SIDE EFFECT; STEREOTACTIC BIOPSY; STEREOTACTIC RADIOSURGERY; THROMBOCYTOPENIA;

EID: 37349053704     PISSN: 09731482     EISSN: 09731482     Source Type: Journal    
DOI: 10.4103/0973-1482.37409     Document Type: Review

References (52)

1. Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumours: The national survey of intracranial neoplasms. Neurology 1985;35:219-26.
2. Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol 1988;45:741-4.
3. Burstein HJ, Leiberman G, Slamon DJ, Winer EP. Isolated central nervous metastases in patients with Her2 overexpressing advanced breast cancer treated with first line trastuzumab based therapy. Ann Oncol 2005;16:1772-7.
4. Gabos Z, Sinha R, Hanson J, Chauhan N. Prognostic significance of epidermal growth factor receptor positivity for development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006;24:5658-63.
5. Duchnowska R, Szczylik. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treatment Reviews 2005;31:312-8.
6. Fortin D, Desjardins A, Benko A, Boudrias M. Blood-brain barrier disruption enhanced chemotherapy in the treatment of malignant brain tumors: the Sherbrooke experience. Cancer 2005;103:2606-15.
7. Tsukada Y, Fouad A, Pickren JW. Central nervous system metastases from breast carcinoma: Autopsy study. Cancer 1983;52:2349-54.
8. DiStefano A, Yap HY, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 1979;44:1913-8.
9. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-3.
10. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10.
11. Kesari S, Batchelor T. Leptomeningeal metastases. Neurol Clin 2003;21:25-66.
12. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 2004;101:1760-6.
13. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, et al. Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival. Ann Oncol 2003;14:1072-7.
14. Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC, Pinder SE, et al. Brain metastases from breast cancer: Identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004;16:345-9.
15. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991;49:650-5.
16. Lee BC, Lee TH, Avraham S, Avraham HK. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2004;2:327-38.
17. Tham YL, Sexton K, Kramer R, Hilsenbeck S. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107:696-704.
18. Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin 2003;21:1-23.
19. Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, et al. Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors and results of a high-dose intrathecal methotrexate regimen. Cancer 1996;77:1315-23.
20. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999;44:275-81.
21. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
22. DeAngelis L, Rogers L, Foley KM. Leptomeningeal metastasis. In: Harris JR, editor. Diseases of the breast. Lippincott Williams and Wilkins: Philadelphia; 2000. p. 867-74.
23. Gaspar L, Scott C, Rotman M. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;43:745-51.
24. Lorenzoni J, Devriendt D, Massager N, David P, Ruíz S, Vanderlinden B, et al. Radiosurgery for treatment of brain metastases: Estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 2004;60:218-24.
25. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989;39:789-96.
26. Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg 1993;79:210-6.
27. Hazuka MB, Burleson WD, Stroud DN, Leonard CE, Lillehei KO, Kinzie JJ. Multiple brain metastases are associated with poor survival in patients treated with surgery and radiotherapy. J Clin Oncol 1993;11:369-73.
28. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998;280:1485-9.
29. Regine WF, Huhn JL, Patchell RA, St Clair WH, Strottmann J, Meigooni A, et al. Risk of symptomatic brain tumour recurrence and neurologic deficit after radiosurgery in patients with newly diagnosed brain metastases: Results and implications. Int J Radiat Oncol Biol Phys 2002;52:333-8.
30. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
31. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33:583-90.
32. Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996;78:1470-6.
33. Suh JH, Stea B, Nabid A, Kresl JJ, Fortin A, Mercier JP, et al. Phase III study of efaproxiral as an adjunct to whole brain radiotherapy for brain metastases. J Clin Oncol 2006;24:106-14.
34. Stea B, Shaw E, Pintér T, Hackman J, Craig M, May J, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer 2006;94:1777-84.
35. Rogers LR, Rock JP, Sills AK, Vogelbaum MA, Suh JH, Ellis TL, et al. Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases. J Neurosurg 2006;105:375-84.
36. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17.
37. Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006;78:255-60.
38. Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001;12:249-54.
39. Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) phase II study. J Neurooncol 2005;71:61-5.
40. Antonadou D, Coliarakis N, Paraskevaidis M. Whole brain radiotherapy alone or in combination with temozolamide for brain metastases: A phase III study. Int J Radiat Oncol Biol Phys 2002;54:93.
41. Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med 1971;111:334-6.
42. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients multiple brain metastases. Int J Radiat Oncol Biol Phys 1999;45:427-34.
43. Chougule PB, Burton-Williams M, Saris. Randomized treatment of brain metastases with gamma knife radiosurgery, whole brain radiotherapy or both. Int J Radiat Oncol Biol Phys 2000;48:114-32.
44. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomized trial. Lancet 2004;363:1665-72.
45. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases a randomized controlled trial. JAMA 2006;295:2483-91.
46. DiLuna ML, King JT, Knisely JP, Chiang VL. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases. Cancer 2007;109:135-45.
47. Varlotto JM, Flickinger JC, Niranjan A, Bhatnagar A, Kondziolka D, Lunsford LD. The impact of whole brain radiotherapyon the long term control and morbidity of patients surviving more than year after gamma knife radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2005;62:1125-32.
48. Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003;8:398-410.
49. Muacevic A, Kreth FW, Tonn C, Wowra B. Stereotactic radiosurgery for multiple brain metastases from breast carcinoma feasibility and outcome of a local treatment concept. Cancer 2004;100:1705-11.
50. Lin NU, Dieras V, Paul D, et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, Illinois. Abstract 1012.
51. Sperduto PW, Berky B, Gasper LE, Mehta M, Curran W, A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1960 patients in the RTOG database, Int J Radiation Oncology Biol. Phys 2007; pp. 1-5, (article in press).
52. Scodan RL, Massard C, Mouret-FourmeE, Guinebretierre JM, Cohen-Solal C, Lalande BD, et al. Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score, Int J Radiation Oncology Biol. Phys., 2007;69:839-45.